These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 445304)

  • 1. Early diagnosis of ovarian cancer.
    Popkin DR
    Can Med Assoc J; 1979 May; 120(9):1106-8. PubMed ID: 445304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comments on the paper by Schröck et al., The simultaneous determination of Ca 125 and D-dimer in plasma and ascitic fluid in ovarian cancer].
    Mezger J
    Onkologie; 1986 Feb; 9(1):10. PubMed ID: 3523340
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibrin degradation products and the diagnosis of ovarian carcinoma.
    Anstey JT; Blythe JG
    Obstet Gynecol; 1978 Nov; 52(5):605-8. PubMed ID: 724180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of 3 markers in ovarian cancer: CA 125, CA 19,9 and CEA].
    Vigné E; Krebs B; Khater R; Mira R; Boublil JL; Jourlait A; Frenay M; Namer M
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(5):609-13. PubMed ID: 3463621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The preoperative diagnosis of malignancy of ovarian cysts.
    Tropé C
    Neoplasma; 1981; 28(1):117-21. PubMed ID: 7279055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
    Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
    Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of epithelial membrane antigen in the diagnosis of ovarian tumors.
    Fujimoto I; Hirai Y; Hasumi K; Masubuchi K; Osamura Y
    Acta Cytol; 1990; 34(4):549-54. PubMed ID: 1695804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum levels of CA 125, CA 19-9, TPA, CEA and CA 50: useful evaluation parameters in the diagnosis of ovarian cancer].
    Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Bianchi R; Fioretti P
    Ann Ostet Ginecol Med Perinat; 1986; 107(4):193-9. PubMed ID: 3467641
    [No Abstract]   [Full Text] [Related]  

  • 9. [CEA determination in aspired fluid of cystic ovarian tumors and ovarian cysts and in ascites and serum samples of patients with ovarian tumors].
    Kunze M; Büttner HH; Strache RR; Voss P; Briese V; Schrodt U
    Zentralbl Gynakol; 1988; 110(16):1006-12. PubMed ID: 3188713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunochemical study of antigens in the ascitic fluid of patients with ovarian cancer].
    Sergeeva NS; Vasil'ev MIu; Avdeev GI
    Eksp Onkol; 1986; 8(4):37-40. PubMed ID: 3757883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal fluid profiles.
    McGowan L
    Natl Cancer Inst Monogr; 1975 Oct; 42():75-9. PubMed ID: 1234638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.
    Whitmore SE; Anhalt GJ; Provost TT; Zacur HA; Hamper UM; Helzlsouer KJ; Rosenshein NB
    Gynecol Oncol; 1997 May; 65(2):241-4. PubMed ID: 9159332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular markers of ovarian carcinoma].
    Dobryszycka W
    Postepy Hig Med Dosw; 2000; 54(4):495-518. PubMed ID: 11016269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The present status of tumor markers in malignant ovarian tumor].
    Nishimura H; Miyoshi T; Hamai J; Miyahara K
    Gan No Rinsho; 1985 May; 31(6 Suppl):589-93. PubMed ID: 2411960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
    Crombach G; Zippel HH; Würz H
    Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cancer of the ovary: the usefulness of Cul-de-sac aspiration and the level of carcino-embryonic antigen in the peritoneal fluid].
    Zylberberg B; Salat-Baroux J; Ravina JH; Demarcourt V; Dormont D
    J Gynecol Obstet Biol Reprod (Paris); 1982; 11(3):365-70. PubMed ID: 7119382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
    Lalos O; Frankendal B; Rudolphi O
    Ann Chir Gynaecol; 1977; 66(3):131-134. PubMed ID: 327909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Distribution of one of the ascitic fluid antigens of ovarian cancer patients in malignant tumors of the stomach and intestines].
    Sergeeva NS; Vasil'ev MIu; Kovalenko TI; Sokolova NV; Avdeev GI
    Eksp Onkol; 1989; 11(2):35-7. PubMed ID: 2661204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.